E Sutton1, J Wade2, J A Lane1,3, M Davis1, E I Walsh1, D E Neal4, F C Hamdy4, M Mason5, J Staffurth6, R M Martin1, C Metcalfe1, T J Peters1, J L Donovan1,7. 1. Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK. 2. Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK. julia.wade@bristol.ac.uk. 3. Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School, Canynge Hall, 39 Whatley Road, Clifton, Bristol, BS8 2PS, UK. 4. Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. 5. Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK. 6. Department of Oncology, Cardiff University, Cardiff, UK. 7. National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) West, University Hospitals Bristol NHS Trust, Bristol, UK.
Abstract
PURPOSE: To investigate men's experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. METHODS: A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences of treatment and its side effects over time. RESULTS: Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bothersome. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects were reported, particularly among men with continuing functional symptoms. CONCLUSIONS: These findings reinforce the importance of providing universal clear, concise, and timely information and supportive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and improve treatment experiences for men undergoing EBRT.
PURPOSE: To investigate men's experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. METHODS: A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences of treatment and its side effects over time. RESULTS: Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bothersome. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects were reported, particularly among men with continuing functional symptoms. CONCLUSIONS: These findings reinforce the importance of providing universal clear, concise, and timely information and supportive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and improve treatment experiences for men undergoing EBRT.
Authors: J Donovan; F Hamdy; D Neal; T Peters; S Oliver; L Brindle; D Jewell; P Powell; D Gillatt; D Dedman; N Mills; M Smith; S Noble; A Lane Journal: Health Technol Assess Date: 2003 Impact factor: 4.014
Authors: Scott A Murray; Marilyn Kendall; Emma Carduff; Allison Worth; Fiona M Harris; Anna Lloyd; Debbie Cavers; Liz Grant; Aziz Sheikh Journal: BMJ Date: 2009-09-28
Authors: Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Scott C Roesch; Linda Adams; Amanda Hines; Alan Palmores; Pearlin Vyas; Cindy Tran; Shannon Pekin; Allison A Vaughn Journal: J Behav Med Date: 2005-06
Authors: A J L King; M Evans; T H M Moore; C Paterson; D Sharp; R Persad; A L Huntley Journal: Eur J Cancer Care (Engl) Date: 2015-01-29 Impact factor: 2.520
Authors: Kelsey L Corrigan; Brian De; Michael K Rooney; Ethan B Ludmir; Prajnan Das; Grace L Smith; Cullen M Taniguchi; Bruce D Minsky; Eugene J Koay; Albert C Koong; Emma B Holliday Journal: Adv Radiat Oncol Date: 2022-04-30